Megaloblastic Anemia — B12 and Folate

• DNA Synthesis Impairment as Central Mechanism: Both B12 and folate are essential cofactors in one-carbon metabolism, which provides the methyl groups and nucleotides required for DNA replication. B12 serves as the cofactor for methionine synthase, which catalyzes the conversion of homocysteine to methionine; simultaneously, this enzyme regenerates tetrahydrofolate (THF) from methyltetrahydrofolate (5-methyl THF). Folate exists primarily in its storage and functional form as THF and its polyglutamate derivatives, which carry one-carbon units for purine and thymidylate synthesis. When either nutrient is deficient, the "methyl trap hypothesis" ensues: B12 deficiency causes accumulation of inert 5-methyl THF, trapping folate in a form unavailable for DNA synthesis; simultaneously, deficient THF reduces both purine synthesis (via phosphoribosyl pyrophosphate amidotransferase) and thymidylate synthesis (via thymidylate synthase). This leads to impaired DNA replication specifically affecting rapidly dividing cells. Erythroid precursors are particularly affected because they represent the most actively proliferating cell line in bone marrow, undergoing 20-30 divisions during normal maturation.

• Nuclear-Cytoplasmic Asynchrony and Megaloblastic Morphology: The defective DNA synthesis causes the nucleus to mature more slowly than the cytoplasm, creating morphologic asynchrony. Erythroid precursors retain immature chromatin patterns (open, dispersed chromatin with a finely stippled appearance) while their cytoplasm achieves hemoglobinization typical of mature RBCs. This asynchrony results in the characteristic megaloblastic precursors on bone marrow examination. The nucleus remains large with immature chromatin despite advanced cytoplasmic maturation, and these abnormal cells are prone to apoptosis within the marrow (ineffective erythropoiesis). The resulting mature RBCs are macrocytic (MCV >100 fL), often with hypersegmented neutrophils and giant metamyelocytes visible on bone marrow, reflecting similar asynchrony in myeloid lineage. Peripheral blood smears show anisocytosis and poikilocytosis; macro-ovalocytes are particularly characteristic of B12 deficiency (whereas folate deficiency produces smaller, rounder macrocytes).

• Neurologic Manifestations in B12 Deficiency — Distinct Pathophysiology: B12 deficiency uniquely causes neurologic disease through several mechanisms. B12 (as methylcobalamin) is required as a cofactor for methionine synthase, and deficiency impairs methylation reactions in myelin formation. Additionally, B12 (as adenosylcobalamin) participates in odd-chain fatty acid oxidation via methylmalonyl-CoA mutase; B12 deficiency causes accumulation of methylmalonic acid and proprionic acid, which may contribute to myelin damage and neuronal dysfunction through oxidative stress mechanisms. The primary sites of demyelination are the dorsal columns and lateral corticospinal tracts, leading to the classic "subacute combined degeneration" syndrome. Critically, these neurologic changes can become irreversible if B12 deficiency is not corrected within months, making early recognition essential. Folate deficiency, despite causing similar hematologic changes, does NOT cause neurologic disease, allowing differentiation between the two conditions.

• Erythropoiesis and Maturation Block: In both B12 and folate deficiency, the block in DNA synthesis predominantly affects G1 phase of the cell cycle, causing prolonged cell cycle time. Erythroid progenitors (BFU-E and CFU-E) are initially preserved or increased in number, reflecting appropriate erythropoietic response to anemia, but their maturation is severely impaired. This results in "ineffective erythropoiesis" where significant numbers of cells die within the marrow (intramedullary hemolysis). Circulating reticulocyte counts are paradoxically low despite anemia and marrow hyperplasia, reflecting the high proportion of immature cells that do not successfully mature. Serum LDH becomes markedly elevated, and indirect bilirubin may be mildly elevated, reflecting the hemolysis occurring within the marrow.

• Impact on Other Cell Lines: Although erythroid cells are most clinically affected, granulopoiesis and megakaryopoiesis are also impaired, though often to a lesser degree. Patients may develop pancytopenia if deficiency is severe or prolonged. Leukopenia occurs from impaired neutrophil production and from shortened neutrophil survival (increased apoptosis). Thrombocytopenia may develop, increasing bleeding risk. Giant metamyelocytes and band forms are characteristically seen on blood smear, reflecting the same nuclear-cytoplasmic asynchrony affecting myeloid precursors.

• Vitamin B12 Deficiency — Pernicious Anemia (Autoimmune): Pernicious anemia represents ~60% of B12 deficiency cases in developed countries and results from autoimmune destruction of gastric parietal cells or autoantibodies against intrinsic factor (IF). Parietal cells produce both hydrochloric acid and intrinsic factor; IF is absolutely required for B12 absorption in the terminal ileum (forming a B12-IF complex that binds cubilin receptors). Autoantibodies develop against parietal cell antigens (particularly proton pump H+/K+-ATPase) or against IF itself. The condition is associated with other autoimmune disorders (thyroiditis, Graves' disease, vitiligo, Addison's disease) and HLA-DQ2/DQ8 haplotypes. Histologically, autoimmune gastritis progresses from type A gastritis (fundal predominance, parietal cell destruction) potentially to atrophic gastritis and intestinal metaplasia. Pernicious anemia shows higher prevalence in Northern European descent populations, particularly those with Scandinavian ancestry. Diagnosis requires demonstration of IF antibodies (present in ~75% of cases) or parietal cell antibodies and evidence of B12 malabsorption via Schilling test or elevated serum methylmalonic acid/homocysteine.

• Dietary B12 Deficiency: While less common than pernicious anemia in developed countries, dietary B12 deficiency remains the leading cause globally, particularly in developing nations. B12 is found exclusively in animal products (meat, poultry, fish, eggs, dairy), making strict vegans at particular risk. Pregnant vegans require special attention as transplacental transfer of B12 occurs even with low maternal levels, potentially leaving infants severely depleted. Unlike absorption-based deficiencies, dietary deficiency develops insidiously over 5-10 years in those with normal body stores (~2-5 mg, sufficient for 3-5 years). Elderly patients with poor nutritional intake, those with alcoholism, and those in resource-limited settings are at highest risk.

• Gastrointestinal B12 Malabsorption — Post-Gastrectomy and Atrophic Gastritis: Any condition affecting the stomach or terminal ileum can impair B12 absorption. Gastrectomy (total or subtotal) removes parietal cells and IF production; B12 deficiency develops in 10-30% of patients within 5 years post-operatively. Atrophic gastritis from chronic autoimmune destruction or from chronic Helicobacter pylori infection reduces IF production and impairs the dissociation of B12 from food proteins. Intestinal disorders affecting the terminal ileum (Crohn's disease, celiac disease, tropical sprue) impair B12 absorption. Bacterial overgrowth syndromes (whether from strictures, diverticula, or achlorhydria) allow bacteria to consume available B12 before it can be absorbed.

• Medications Impairing B12 Absorption and Metabolism: Metformin impairs B12 absorption via an unclear mechanism (possibly reduced IF binding or intrinsic ileal dysfunction); 10-30% of long-term users develop B12 deficiency. Proton pump inhibitors (PPIs) and H2-receptor antagonists reduce gastric acid and pepsinogen, impairing the release of protein-bound B12 from food; deficiency develops after 2+ years of use, particularly in those >60 years. Nitrous oxide (N2O) irreversibly inactivates B12 by oxidizing the cobalt atom; even brief recreational exposure can cause deficiency in those with marginal stores. Orlistat (pancreatic lipase inhibitor) may impair B12 absorption. Colchicine damages the terminal ileum, impairing B12 absorption.

• Folate Deficiency — Dietary Insufficiency: Dietary folate deficiency is the leading cause of folate deficiency globally. Folate is found in leafy greens, legumes, nuts, and fortified grains, but is heat-labile and easily destroyed by cooking. Patients with poor dietary intake (alcoholics, elderly with limited intake, those with eating disorders, those in poverty) develop deficiency relatively rapidly within 3-4 months because body stores of folate are limited (~5-20 mg). Alcoholism is a particularly common cause: ethanol impairs folate absorption in the proximal small intestine and inhibits folate metabolism; additionally, alcoholics often have poor nutritional intake.

• Increased Folate Demands: Pregnancy increases folate requirements 2-3 fold due to rapid fetal growth and expanded maternal blood volume. Lactation similarly increases demands. Hemolytic anemias, thalassemia, and other chronic hemolytic conditions increase folate consumption for accelerated RBC production. Psoriasis and other conditions with rapid skin cell turnover increase folate demands. Malignancy, particularly rapidly dividing tumors, increases folate consumption.

• Gastrointestinal Folate Malabsorption: Celiac disease damages the proximal small intestine (primary site of folate absorption), causing folate deficiency in a subset of patients. Tropical sprue (seen in endemic areas of Caribbean, Southeast Asia, India) causes mucosal damage and folate/B12 malabsorption. Crohn's disease affecting the proximal small intestine impairs folate absorption. Short bowel syndrome from surgical resection or severe inflammatory bowel disease reduces absorptive surface.

• Medications Impairing Folate Metabolism: Methotrexate inhibits dihydrofolate reductase, blocking the conversion of dihydrofolate to THF; this is dose-dependent and seen at therapeutic doses used for malignancy or autoimmune disease. Trimethoprim (and to lesser degree sulfamethoxazole) inhibits bacterial dihydrofolate reductase but also affects human enzyme, causing folate deficiency with prolonged use or in those with marginal stores. Phenytoin, phenobarbital, and primidone increase folate catabolism and decrease absorption; deficiency develops in 10-20% of chronic users. 5-Fluorouracil is a thymidylate synthase inhibitor that causes folate deficiency. Sulfasalazine impairs folate absorption in the proximal small bowel.

• Anemia Symptoms — Insidious Onset: Patients typically present with gradually progressive symptoms of anemia: fatigue, dyspnea on exertion, palpitations, and reduced exercise tolerance. The insidious nature of onset (developing over weeks to months) allows some degree of cardiopulmonary compensation; patients may not seek care until hemoglobin drops below 7-8 g/dL or until they develop specific triggering symptoms. Elderly patients may present with confusion, functional decline, or exacerbation of underlying heart disease rather than classic anemia symptoms. Some patients present with incidental finding of macrocytosis on routine laboratory work without recognized symptoms.

• Neurologic Manifestations of B12 Deficiency — Subacute Combined Degeneration (SCD): This constellation of neurologic findings is pathognomonic for B12 deficiency and does not occur with folate deficiency, making it critical for differential diagnosis. Classic presentation includes progressive paresthesias (typically starting distally in lower extremities), followed by development of spasticity, hyperreflexia, and later Babinski signs reflecting lateral corticospinal tract involvement. Patients develop progressive gait imbalance and loss of vibration and proprioception from dorsal column involvement (presenting as sensory ataxia). Cognitive changes ranging from mild memory impairment to frank dementia ("megaloblastic madness") may develop. Optic neuropathy (subacute combined degeneration affecting optic nerves) presents with visual blurring and central scotomas. Neuropsychiatric symptoms including personality changes, irritability, depression, and psychosis can occur. The timing of neurologic onset relative to hematologic findings is variable: some patients present with neurologic symptoms before significant anemia develops (particularly those with pernicious anemia due to slower onset), while others present with advanced anemia and minimal neurologic disease. Critically, neurologic changes become increasingly irreversible after 6-12 months of deficiency; early recognition and treatment are essential.

• Glossitis and Oral Findings: Both B12 and folate deficiency can cause glossitis (inflammation of the tongue), presenting as soreness, beefy red appearance, and loss of papillae ("bald tongue"). Patients may report difficulty eating or altered taste sensation. Angular cheilitis (cracks at the corners of the mouth) may occur. Oral ulceration can develop. These findings reflect impaired epithelial cell turnover from defective DNA synthesis.

• Gastrointestinal Symptoms: Diarrhea is common in B12 deficiency (occurring in ~20% of patients) and may be multifactorial: bacterial overgrowth from achlorhydria, direct effects of B12 deficiency on enteric neurons, or associated pancreatic insufficiency (from atrophic gastritis affecting exocrine pancreas). Constipation may also occur. Anorexia and weight loss can develop. Abdominal discomfort is less common. In pernicious anemia, patients may report symptoms of gastritis (epigastric discomfort).

• Cardiovascular Manifestations: Severe anemia (Hgb <7 g/dL) may precipitate high-output heart failure, exertional angina, or syncope. Patients with underlying coronary artery disease or cardiomyopathy are at particular risk. Tachycardia is common even at mild anemia levels.

• Physical Examination Findings: Pallor of conjunctivae, palms, and nail beds reflects reduced hemoglobin. Jaundice may be present from mild indirect hyperbilirubinemia due to ineffective erythropoiesis. In B12 deficiency, vibration sense loss and proprioception loss are the earliest neurologic signs, appreciated first in lower extremities. Positive Romberg test reflects sensory ataxia. Hyperreflexia (particularly in lower extremities initially) and Babinski signs develop as corticospinal tract involvement progresses. Gait examination reveals sensory ataxia (wide-based, cautious gait with visual compensation). Mental status changes may range from subtle memory impairment to frank confusion. Fundoscopic examination may reveal subtle pallor of optic disc. Tachycardia and tachypnea are present with significant anemia.

• Laboratory Findings on Presentation: Complete blood count reveals macrocytic anemia (MCV typically 100-140 fL, occasionally >140 fL in severe deficiency). RBC count is often disproportionately low relative to the degree of anemia (RBC count may be normal or low despite low hemoglobin). Peripheral blood smear shows macro-ovalocytes (in B12 deficiency) or rounder macrocytes (folate deficiency), anisocytosis, and poikilocytosis. Hypersegmented neutrophils (≥6 nuclear lobes) are seen in approximately

Initial testing

• CBC with indices and peripheral smear: macrocytic anemia with MCV usually >100 fL; look for macro-ovalocytes and hypersegmented neutrophils (≥5% with 5 lobes, or any with ≥6 lobes), the earliest and most specific smear clue.
• Reticulocyte count: inappropriately low for the degree of anemia — the signature of ineffective erythropoiesis. A high reticulocyte count points instead to hemolysis or bleeding as the cause of macrocytosis.
• Hemolysis panel: markedly elevated LDH with low haptoglobin and mildly elevated indirect bilirubin, reflecting intramedullary destruction rather than peripheral hemolysis.

Establishing which vitamin

• Serum B12 and serum folate: a clearly low B12 (conventionally <200 pg/mL) or low serum folate establishes deficiency, but the indeterminate zone (roughly 200–300 pg/mL) is common and normal levels do not exclude tissue deficiency, since much circulating B12 is bound to haptocorrin and unavailable to cells.
• Metabolite confirmation (functional gold standard): methylmalonic acid (MMA) rises only in B12 deficiency (loss of methylmalonyl-CoA mutase activity), while homocysteine rises in both B12 and folate deficiency (loss of methionine synthase flux). Elevated MMA plus elevated homocysteine = B12; normal MMA with elevated homocysteine = folate. The British Society for Haematology cobalamin/folate guideline endorses metabolite testing when serum levels are borderline or clinically discordant.
• RBC folate reflects stores over the preceding months and is less affected by a recent meal than serum folate.

Etiologic work-up

• Anti-intrinsic factor antibody: highly specific for pernicious anemia but insensitive; anti-parietal cell antibody is more sensitive and less specific. Supportive findings include hypergastrinemia and low pepsinogen I from fundic atrophy. The Schilling test is of historical/exam interest only — radiolabeled B12 is no longer available in the US.
• Bone marrow biopsy is rarely required; it shows hypercellularity, megaloblastic erythroid precursors, and giant bands and metamyelocytes. Reserve it for suspected myelodysplastic syndrome or unexplained pancytopenia.
• Exclude non-megaloblastic macrocytosis: alcohol, liver disease, hypothyroidism, MDS, and reticulocytosis — none produce hypersegmented neutrophils.

Immediate considerations

• Transfusion is usually unnecessary and potentially harmful: chronic anemia is volume-expanded, and rapid transfusion can precipitate pulmonary edema. Reserve it for hemodynamic instability, active ischemia, or profound symptomatic anemia, and transfuse slowly, one unit at a time.
• Never give folate alone when B12 deficiency has not been excluded. Folate corrects the anemia while the neurologic lesion progresses, and by removing the hematologic clue it delays diagnosis of subacute combined degeneration. Draw B12/MMA before starting any repletion.

First-line therapy

• Cobalamin replacement: parenteral cyanocobalamin 1000 mcg IM, given as a loading series (commonly daily to weekly for several weeks) then monthly for life in pernicious anemia, gastrectomy, or ileal disease. The British Society for Haematology recommends more intensive initial dosing when neurologic features are present.
• High-dose oral cyanocobalamin (1000–2000 mcg daily) is an accepted alternative even in pernicious anemia, because roughly 1% of an oral dose is absorbed by passive diffusion independent of intrinsic factor. Adherence must be reliable; parenteral therapy is preferred initially for neurologic disease or malabsorptive states.
• Folate replacement: oral folic acid 1 mg daily until stores and the cause are corrected; continue indefinitely in chronic hemolysis or ongoing malabsorption.

Adjunctive and preventive

• Treat the cause: stop or mitigate offending drugs (metformin, PPIs, phenytoin, nitrous oxide), treat celiac disease or bacterial overgrowth, and give leucovorin (folinic acid) rescue for methotrexate toxicity, since methotrexate blocks dihydrofolate reductase and folic acid cannot bypass it.
• Preconception folate: the USPSTF recommends 0.4–0.8 mg folic acid daily for all persons planning or capable of pregnancy to prevent neural tube defects; ACOG endorses supplementation with higher doses after an affected pregnancy.

Monitoring response

• Reticulocytosis within about a week confirms the diagnosis retrospectively; check potassium during early recovery and reassess iron, as brisk erythropoiesis can unmask iron deficiency and leave the MCV falsely normal.

Disease-related

• Irreversible subacute combined degeneration: prolonged demyelination of the dorsal columns and lateral corticospinal tracts fixes the deficit; signaled by persistent sensory ataxia, spasticity, and Babinski signs that fail to improve after months of repletion. Neurologic B12 deficiency is a treat-now situation — do not wait for confirmatory metabolites.
• Severe pancytopenia: ineffective myelopoiesis and megakaryopoiesis produce neutropenic fever or bleeding. Emergency.
• Pseudo-thrombotic microangiopathy: severe B12 deficiency can produce schistocytes, very high LDH, low haptoglobin, and thrombocytopenia, mimicking TTP. The discriminators are a low reticulocyte count, MCV >100 fL, hypersegmented neutrophils, and normal ADAMTS13. Misdiagnosis leads to unnecessary plasma exchange. Emergency-level distinction.
• High-output heart failure and demand ischemia in profound anemia. Emergency.
• Gastric neoplasia in pernicious anemia: autoimmune atrophic gastritis predisposes to gastric adenocarcinoma and, via achlorhydria-driven hypergastrinemia and enterochromaffin-like cell hyperplasia, to type 1 gastric carcinoid. The AGA clinical practice update on atrophic gastritis supports endoscopic assessment and risk-stratified surveillance; new dyspepsia, iron deficiency, or weight loss should prompt endoscopy.
• Fetal neural tube defects from periconceptional folate deficiency, and possible fetal neurologic injury with maternal B12 deficiency.
• Hyperhomocysteinemia, associated with vascular and thrombotic risk, though lowering it with vitamins has not been shown to reduce cardiovascular events.

Treatment-related

• Hypokalemia during repletion: the burst of erythropoiesis drives potassium intracellularly within the first days of therapy, risking arrhythmia in patients already depleted or on diuretics. Emergency if severe — monitor and replace.
• Unmasked iron deficiency: rapid hemoglobin synthesis consumes iron stores; the clue is a plateauing hemoglobin with a falling MCV and low ferritin.
• Masked B12 deficiency from folic acid monotherapy: hematologic response with continued neurologic decline.
• Rebound thrombocytosis in the first weeks of recovery, usually transient.

• MMA separates the two: elevated methylmalonic acid and homocysteine = B12 deficiency; elevated homocysteine with normal MMA = folate deficiency. This is the single most tested biochemical discriminator.
• Neurologic findings mean B12, never folate: subacute combined degeneration — vibration and proprioception loss first, then spasticity, hyperreflexia, and Babinski signs. Folate deficiency reproduces the entire hematologic picture with a normal neurologic exam.
• Hypersegmented neutrophils are the earliest and most specific smear finding, appearing before the MCV rises and persisting after treatment begins.
• Low reticulocyte count with high LDH and low haptoglobin is the ineffective-erythropoiesis signature. A stem with anemia, jaundice, and sky-high LDH is not always hemolysis — check the MCV and the smear.
• Best next step when neurologic B12 deficiency is suspected: draw B12 and MMA, then start cobalamin immediately. Do not give folic acid alone — it corrects the anemia and lets the myelopathy progress.
• The association examiners love: pernicious anemia → anti-intrinsic factor antibody (specific), autoimmune atrophic gastritis, hypergastrinemia, and increased risk of gastric adenocarcinoma and type 1 gastric carcinoid; clusters with Hashimoto thyroiditis and vitiligo.
• Drug and exposure triggers: metformin and chronic PPI use (B12 malabsorption), nitrous oxide abuse (oxidizes cobalt, precipitating abrupt myeloneuropathy in a young dental worker or recreational user), phenytoin and trimethoprim (folate), methotrexate (requires leucovorin, not folic acid, for rescue).
• Common distractors: a normal MCV does not exclude B12 deficiency when concurrent iron deficiency or thalassemia is present — look at the RDW and smear for a dimorphic population; and severe B12 deficiency with schistocytes and thrombocytopenia mimics TTP, but the low reticulocyte count, high MCV, and normal ADAMTS13 mean cobalamin, not plasma exchange.